Sequana Medical NV (SEQUA.BR)

1.4400 -0.0350 (-2.37%) At close: 04:17PM CEST

Sequana Medical NV

Kortrijksesteenweg 1112
Bus 102 Sint-Denijs-Westrem
Gent 9051
Belgium
32 9 298 28 28
https://www.sequanamedical.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ian Crosbie	CEO & Executive Director	463.6k	N/A	N/A
Ms. Kirsten Van Bockstaele	Chief Financial Officer	354.14k	N/A	1975
Ms. Lies Vanneste	Director of Investor Relations	N/A	N/A	N/A
Mr. Martijn Blom	Chief Commercial Officer	N/A	N/A	1974
Dr. Oliver Godje M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1965

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Corporate governance

Sequana Medical NV’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.